KR20250005183A - 사회적/정서적 고립 또는 분리의 치료를 위한 5-메톡시-n,n-디메틸트립타민 - Google Patents
사회적/정서적 고립 또는 분리의 치료를 위한 5-메톡시-n,n-디메틸트립타민 Download PDFInfo
- Publication number
- KR20250005183A KR20250005183A KR1020247035762A KR20247035762A KR20250005183A KR 20250005183 A KR20250005183 A KR 20250005183A KR 1020247035762 A KR1020247035762 A KR 1020247035762A KR 20247035762 A KR20247035762 A KR 20247035762A KR 20250005183 A KR20250005183 A KR 20250005183A
- Authority
- KR
- South Korea
- Prior art keywords
- dmt
- meo
- pharmaceutically acceptable
- acceptable salt
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22000083.0 | 2022-03-27 | ||
| EP22000086 | 2022-03-27 | ||
| EP22000086.3 | 2022-03-27 | ||
| EP22000083 | 2022-03-27 | ||
| EP23153995.8 | 2023-01-30 | ||
| EP23153939 | 2023-01-30 | ||
| EP23153995 | 2023-01-30 | ||
| EP23153939.6 | 2023-01-30 | ||
| PCT/EP2023/057876 WO2023186829A1 (en) | 2022-03-27 | 2023-03-27 | 5-methoxy-n,n-dimethyltryptamine for the treatment of social/emotional withdrawal or detachment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250005183A true KR20250005183A (ko) | 2025-01-09 |
Family
ID=86007166
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247035762A Pending KR20250005183A (ko) | 2022-03-27 | 2023-03-27 | 사회적/정서적 고립 또는 분리의 치료를 위한 5-메톡시-n,n-디메틸트립타민 |
| KR1020247035758A Pending KR20250005181A (ko) | 2022-03-27 | 2023-03-27 | 인지 기능장애 치료 |
| KR1020247035718A Pending KR20250005176A (ko) | 2022-03-27 | 2023-03-27 | 수면 장애 치료에 사용하기 위한 5-meo-dmt |
| KR1020247035659A Pending KR20240167879A (ko) | 2022-03-27 | 2023-03-27 | 정신운동 지연의 치료를 위한 5-메톡시-n,n-디메틸트립타민 |
| KR1020247035746A Pending KR20250005179A (ko) | 2022-03-27 | 2023-03-27 | 불안의 치료 |
| KR1020247035653A Pending KR20250005170A (ko) | 2022-03-27 | 2023-03-27 | 양극성 장애의 치료를 위한 5-메톡시-n,n-디메틸트립타민 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247035758A Pending KR20250005181A (ko) | 2022-03-27 | 2023-03-27 | 인지 기능장애 치료 |
| KR1020247035718A Pending KR20250005176A (ko) | 2022-03-27 | 2023-03-27 | 수면 장애 치료에 사용하기 위한 5-meo-dmt |
| KR1020247035659A Pending KR20240167879A (ko) | 2022-03-27 | 2023-03-27 | 정신운동 지연의 치료를 위한 5-메톡시-n,n-디메틸트립타민 |
| KR1020247035746A Pending KR20250005179A (ko) | 2022-03-27 | 2023-03-27 | 불안의 치료 |
| KR1020247035653A Pending KR20250005170A (ko) | 2022-03-27 | 2023-03-27 | 양극성 장애의 치료를 위한 5-메톡시-n,n-디메틸트립타민 |
Country Status (9)
| Country | Link |
|---|---|
| US (9) | US20250241893A1 (https=) |
| EP (7) | EP4499088A1 (https=) |
| JP (6) | JP2025510912A (https=) |
| KR (6) | KR20250005183A (https=) |
| CN (2) | CN119095595A (https=) |
| AU (6) | AU2023246774A1 (https=) |
| CA (6) | CA3255348A1 (https=) |
| IL (6) | IL315899A (https=) |
| WO (9) | WO2023186820A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| EP4155306A1 (en) | 2021-01-15 | 2023-03-29 | Beckley Psytech Limited | Neuroactive ergoline analogue |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202306256D0 (en) * | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026078143A1 (en) | 2024-10-09 | 2026-04-16 | GH Research Ireland Limited | Combinations of 5-meo-dmt with antidepressants for treating depression |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19803376C1 (de) | 1998-01-29 | 1999-10-14 | Markus Storz | Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten |
| US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US20040234916A1 (en) | 2003-05-21 | 2004-11-25 | Alexza Molecular Delivery Corporation | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| ES2355983T3 (es) | 2006-08-01 | 2011-04-01 | STOBI GMBH & CO. KG | Balón de válvula para inhaladores . |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| FI4349407T3 (fi) | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
| HUE069534T2 (hu) * | 2019-02-22 | 2025-03-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra |
| US12377112B2 (en) * | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| EP3868364A1 (en) * | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| WO2021216489A1 (en) * | 2020-04-20 | 2021-10-28 | Lobe Sciences Ltd. | Methods for treating mild traumatic brain injury, post traumatic stress disorder and mild traumatic brain injury |
| BR112022025306A2 (pt) * | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| US11406619B2 (en) * | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US20240299353A1 (en) | 2021-03-12 | 2024-09-12 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
-
2023
- 2023-03-27 IL IL315899A patent/IL315899A/en unknown
- 2023-03-27 CA CA3255348A patent/CA3255348A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057867 patent/WO2023186820A1/en not_active Ceased
- 2023-03-27 EP EP23717412.3A patent/EP4499088A1/en active Pending
- 2023-03-27 CA CA3255340A patent/CA3255340A1/en active Pending
- 2023-03-27 KR KR1020247035762A patent/KR20250005183A/ko active Pending
- 2023-03-27 US US18/850,376 patent/US20250241893A1/en active Pending
- 2023-03-27 AU AU2023246774A patent/AU2023246774A1/en active Pending
- 2023-03-27 KR KR1020247035758A patent/KR20250005181A/ko active Pending
- 2023-03-27 IL IL315902A patent/IL315902A/en unknown
- 2023-03-27 WO PCT/EP2023/057870 patent/WO2023186823A1/en not_active Ceased
- 2023-03-27 EP EP23717035.2A patent/EP4499075A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057857 patent/WO2023186816A1/en not_active Ceased
- 2023-03-27 AU AU2023242291A patent/AU2023242291A1/en active Pending
- 2023-03-27 IL IL315898A patent/IL315898A/en unknown
- 2023-03-27 IL IL315891A patent/IL315891A/en unknown
- 2023-03-27 KR KR1020247035718A patent/KR20250005176A/ko active Pending
- 2023-03-27 EP EP23717036.0A patent/EP4499076A1/en not_active Withdrawn
- 2023-03-27 WO PCT/EP2023/057842 patent/WO2023186806A1/en not_active Ceased
- 2023-03-27 CA CA3255505A patent/CA3255505A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057877 patent/WO2023186830A1/en not_active Ceased
- 2023-03-27 US US18/851,346 patent/US20250241895A1/en active Pending
- 2023-03-27 CA CA3255629A patent/CA3255629A1/en active Pending
- 2023-03-27 KR KR1020247035659A patent/KR20240167879A/ko active Pending
- 2023-03-27 EP EP23717033.7A patent/EP4499073A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057883 patent/WO2023186835A1/en not_active Ceased
- 2023-03-27 JP JP2024557191A patent/JP2025510912A/ja active Pending
- 2023-03-27 JP JP2024557759A patent/JP2025510369A/ja active Pending
- 2023-03-27 AU AU2023246543A patent/AU2023246543A1/en active Pending
- 2023-03-27 EP EP23717042.8A patent/EP4499082A1/en active Pending
- 2023-03-27 US US18/850,383 patent/US20250205256A1/en not_active Abandoned
- 2023-03-27 JP JP2024557755A patent/JP2025511081A/ja active Pending
- 2023-03-27 JP JP2024557758A patent/JP2025510368A/ja active Pending
- 2023-03-27 US US18/850,362 patent/US20250241892A1/en active Pending
- 2023-03-27 CN CN202380030914.XA patent/CN119095595A/zh active Pending
- 2023-03-27 IL IL315897A patent/IL315897A/en unknown
- 2023-03-27 IL IL315896A patent/IL315896A/en unknown
- 2023-03-27 WO PCT/EP2023/057876 patent/WO2023186829A1/en not_active Ceased
- 2023-03-27 CA CA3255343A patent/CA3255343A1/en active Pending
- 2023-03-27 CA CA3255648A patent/CA3255648A1/en active Pending
- 2023-03-27 AU AU2023244452A patent/AU2023244452A1/en active Pending
- 2023-03-27 KR KR1020247035746A patent/KR20250005179A/ko active Pending
- 2023-03-27 JP JP2024557205A patent/JP2025510916A/ja active Pending
- 2023-03-27 US US18/850,348 patent/US20250241891A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057827 patent/WO2023186797A1/en not_active Ceased
- 2023-03-27 EP EP23717031.1A patent/EP4499226A1/en active Pending
- 2023-03-27 EP EP23717043.6A patent/EP4499083A1/en active Pending
- 2023-03-27 US US18/851,343 patent/US20250213532A1/en active Pending
- 2023-03-27 AU AU2023246545A patent/AU2023246545A1/en active Pending
- 2023-03-27 US US18/850,370 patent/US20250205199A1/en active Pending
- 2023-03-27 AU AU2023246679A patent/AU2023246679A1/en active Pending
- 2023-03-27 KR KR1020247035653A patent/KR20250005170A/ko active Pending
- 2023-03-27 WO PCT/EP2023/057873 patent/WO2023186826A1/en not_active Ceased
- 2023-03-27 JP JP2024557204A patent/JP2025512831A/ja active Pending
- 2023-03-27 CN CN202380031464.6A patent/CN119053327A/zh active Pending
- 2023-09-27 US US18/373,903 patent/US20240108601A1/en active Pending
- 2023-09-27 US US18/373,906 patent/US20240108602A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20250005183A (ko) | 사회적/정서적 고립 또는 분리의 치료를 위한 5-메톡시-n,n-디메틸트립타민 | |
| KR20250005184A (ko) | 사회적/감정적 위축 또는 분리의 치료를 위한 5-메톡시-n,n-다이메틸트립타민 | |
| KR20250139377A (ko) | 수유부의 정신 장애 치료에 사용하기 위한 5-메톡시-n,n-다이메틸트립타민 | |
| KR20250138805A (ko) | 정신 장애의 치료 | |
| KR20250005172A (ko) | 정신 장애의 치료 | |
| CN118973568A (zh) | 精神障碍的治疗 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |